CORT250117P50000
- 2.30
- -0.80-25.81%
Corcept Therapeutics Newsroom
CCORF Maintains Corcept Therapeutics(CORT.US) With Buy Rating, Maintains Target Price $78
Truist Financial Maintains Corcept Therapeutics(CORT.US) With Buy Rating
Corcept Therapeutics (CORT) Receives a Buy From Truist Financial
CCORF Maintains Corcept Therapeutics(CORT.US) With Buy Rating, Maintains Target Price $78
CCORF Maintains Corcept Therapeutics(CORT.US) With Buy Rating, Maintains Target Price $78
Piper Sandler Maintains Corcept Therapeutics(CORT.US) With Buy Rating, Maintains Target Price $67
Truist Financial Maintains Corcept Therapeutics(CORT.US) With Buy Rating
Truist Financial Keeps Their Buy Rating on Corcept Therapeutics (CORT)
A Quick Look at Today's Ratings for Corcept Therapeutics(CORT.US), With a Forecast Between $67 to $80
Corcept Therapeutics Analyst Ratings
Truist Financial Maintains Corcept Therapeutics(CORT.US) With Buy Rating
Corcept Therapeutics Is Maintained at Buy by HC Wainwright & Co.
Corcept Therapeutics Analyst Ratings
H.C. Wainwright Maintains Corcept Therapeutics(CORT.US) With Buy Rating, Raises Target Price to $80
Truist Financial Maintains Corcept Therapeutics(CORT.US) With Buy Rating, Announces Target Price $76
CCORF Maintains Corcept Therapeutics(CORT.US) With Buy Rating, Maintains Target Price $78
Buy Rating Affirmed for Corcept Therapeutics Amid Strong Financials and Promising Clinical Trials
Truist Financial Maintains Corcept Therapeutics(CORT.US) With Buy Rating
Truist Financial Gives a Buy Rating to Corcept Therapeutics (CORT)
Corcept Therapeutics Is Maintained at Overweight by Piper Sandler